CTLA4 and neoplasm: Notably, first-line FLOT chemotherapy regimen upregulated CTLA-4 on the surface of T cells which might be a potential mechanism for promoting disease progression and suppressing anti-tumor immunity leading to inferior responses to neoadjuvant regiments (37).